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In recent years, protein lysine acetylation has emerged as a prominent and conserved regulatory posttranslational modiﬁcation
that is abundant on numerous enzymes involved in the processes of intermediary metabolism. Well-characterized mitochondrial
processes of carbon utilization are enriched in acetyl-lysine modiﬁcations. Although seminal discoveries have been made in the
basic biology of mitochondrial acetylation, an understanding of how acetylation states inﬂuence enzyme function and metabolic
reprogramming during pathological states remains largely unknown. This paper will examine our current understanding of
eukaryotic acetate metabolism and present recent ﬁndings in the ﬁeld of mitochondrial acetylation biology. The implications of
mitochondrial acetylation for the aging process will be discussed, as well as its potential implications for the unique and localized
metabolic states that occur during the aging-associated conditions of heart failure and cancer growth.
1.Introduction
Over millions of years, eukaryotic organisms evolved ﬁne-
tuned metabolic mechanisms for orchestrating the conver-
sion of diverse carbon substrates into cellular energy. These
mechanisms include changes in gene transcription, allosteric
regulationofmetabolicenzymesbyﬂuxingpoolsofinterme-
diary metabolites, and direct regulation by posttranslational
modiﬁcations (PTMs), such as phosphorylation. One PTM,
lysine acetylation, has been traditionally studied in the
context of nuclear histone modiﬁcations and is well known
to inﬂuence changes in gene expression [1]. However, recent
proteomics surveys have revealed that lysine acetylation is a
widespread cellular modiﬁcation that is particularly abun-
dant on mitochondrial proteins, suggesting a new posttrans-
lational mechanism for coordinating the metabolism of car-
bon sources [2, 3]. Accordingly, several studies have demon-
strated that reversible lysine acetylation can, by targeting key
enzymes, modulate the activity of mitochondria-localized
fatty acid β-oxidation, the tricarboxylic acid cycle (TCA),
urea cycle, and oxidative phosphorylation in a nutrient-
responsive manner [4–7]. The reversible and nutrient-
sensitive manner of many of these acetyl modiﬁcations has
strongly implicated the mitochondrial-localized members of
the NAD+-dependent deacetylases (sirtuins) as regulatory
mediators of these fundamental metabolic processes [8].
Sirtuins are also believed to be part of a genetic program
inﬂuencing the development of age-related conditions such
as heart disease, neurodegenerative disease, and cancer
[9]. Although seminal discoveries have been made in the
basicbiologyofmitochondrialacetylation,anunderstanding
of how acetylation states inﬂuence enzyme function and
metabolic reprogramming during age-associated patholog-
ical states remains largely unknown.
In this paper we will review mammalian acetate
metabolism and provide a brief history of lysine acetylation
as a means to discussing more recent advances in mito-
chondrial acetylation biology. We then suggest a role for
alterations in mitochondrial acetylation states during age-
related conditions of heart failure and cancer, as well as
review its potential role in human longevity.
2.Acetyl-CoAandMetabolism
Acetate is an ancient energy precursor molecule of metazoan
metabolism (Figure 1). In eukaryotic systems, the principal2 Journal of Aging Research
source of cellular acetate is generated by the mitochondrial
processes of glucose-derived pyruvate oxidation, amino acid
catabolism, and the oxidation of even-numbered fatty acyl
chains. These distinct metabolic pathways are all capable of
yielding the activated form of cellular acetate, or acetyl-CoA.
Thus, acetyl-CoA represents a common convergence point
for carbohydrate, amino acid, and lipid catabolism. How
mitochondrial acetyl-CoA is utilized throughout the cell is
heavily dependent on the cell type and the metabolic state
of the organism. However, the primary function of acetyl-
CoA throughout all cell types is as a carbon donor in the
tricarboxylic acid (TCA) cycle. Originally characterized by
Hans Krebs and Albert Szent-Gy¨ orgyi, the TCA cycle is a
series of substrate oxidation and decarboxylation reactions
that serve to liberate carbon dioxide and generate electron
donors in the form of the reduced coenzymes nicotinamide
adenine dinucleotide (NADH) and ﬂavin adenine dinu-
cleotide (FADH2)[ 10]. The coenzymes NADH and FADH2,
in turn, serve as high-energy electron donors which are
oxidized by the respiratory chain complexes to generate the
proton-motive electrochemical gradient that is ultimately
responsible the formation of energy-rich ATP [11]. Acetyl-
CoA also serves as a vital component of anabolic cellular
processes. In general, during a state of nutrient excess (fed
state), a proportion of the excess acetyl-CoA generated
within the mitochondria is exported into the cytosol in
the form of citrate, where it is reconverted into acetyl-
CoA by ATP-citrate lyase [12]. This cytosolic acetyl-CoA
can then participate in de novo synthesis of fatty acids and
sterols that are vitally important for the formation and
maintenance of lipid membranes, as well as the synthesis
of steroid hormones, triacylglycerols, cholesterol, and fat-
soluble vitamins [13, 14]. Lipogenesis primarily occurs in
hepatocytes and adipocytes, whereas cholesterol synthesis
primarily occurs in hepatocytes. In contrast to the fed state,
during a nutrient-depleted state, the liver uses TCA cycle
intermediates for gluconeogenesis which depletes oxaloac-
etate and limits the entry of acetyl-CoA into the TCA cycle.
As the liver continues to oxidize fatty acids for fuel, acetyl-
CoAbeginstoaccumulateandisconvertedintothetransport
forms of acetate known as ketone bodies. Ketone bodies
are then used as an alternative fuel source in the brain,
heart, and skeletal muscle during fasting or glucose-scarce
conditions [15]. Free cytoplasmic and mitochondrial acetate
canalsobeconvertedintoacetyl-CoAviatheATP-dependent
mechanisms of acetyl-CoA synthetase 1 and 2, respectively
[16, 17]. Interestingly, acetyl-CoA synthetase 2 (AceCS2)
was recently found to be an enzyme critically involved in
thermogenesis during fasting conditions [18]. Through its
well-establishedrolesinthegenerationofcellularenergyand
as a macromolecular building block, acetyl-CoA stands as
a critical chemical intermediate that is inextricably linked
to cellular energy homeostasis. However, the fundamental
and ancient link between acetyl-CoA, mitochondria, and
metabolism is underappreciated in the context of acetyl-
CoA’s exciting and dynamic use as the acetyl group donor for
acetyl-lysine posttranslational modiﬁcations. Interestingly,
a recent study highlighted this often overlooked aspect of
acetyl-CoA metabolism by demonstrating that the metabolic
enzyme ATP-citrate lyase, in addition to its previously
mentioned roles in lipid and steroid synthesis, also regulates
global patterns of histone acetylation and corresponding
c h a n g e si ng e n ee x p r e s s i o n[ 19]. Therefore, it is nutrient
availability and metabolism that largely determine the cel-
lular pool of acetyl-CoA available for acetyl-lysine protein
modiﬁcations.
3. Nε-Acetylation
Acetylation occurring on the epsilon-amino group of lysine
residues (Nε-acetylation) was discovered on histone proteins
puriﬁed from calf thymus over forty years ago [20]. The
ensuing studies of Nε-acetylation focused almost exclusively
on histone substrates [21–23]. It was not until 1996 that
Taunton et al. puriﬁed the ﬁrst histone deacetylase enzyme
[24]. This important discovery quickly expanded research
interest in the ﬁeld of histone acetylation and in the past
15 years has led to the discovery of numerous enzymes that
catalyze the addition and removal of acetyl groups, termed
histone acetyltransferases (HATs) and histone deacetylases
(HDACs), respectively. The dynamic and opposing functions
of HATs and HDACs form the basis for the transcriptional
modulation of chromatin and the histone code hypothesis
[1, 25]. Due to their role in global cellular processes of tran-
scription, HDACs have become attractive chemotherapeutic
targets. Vorinostat (suberoylanilide hydroxamic acid) and
Romidepsin (FK228) are FDA-approved HDAC inhibitors
that are currently being used for the treatment of cutaneous
T-cell lymphomas, and there are a number of related
compounds in clinical trials for other neoplastic indications
[26].
Owing to the highly conserved nature of HATs and
HDACs across multiple eukaryotic species, we commonly
classify them according to their homologs in yeast [27].
There are three primary families of HATs. These include
the MYST family, the Gcn-5-related N-acetyltransferases
(GNATs), and the E1A-associated protein of 300kDa/CREB-
binding protein (p300/CBP) family [28]. HDACs are broadly
classiﬁed into the Rpd3/Hda1 family of deacetylases, and the
silent information regulator-2-(Sir2-) like NAD+-dependent
deacetylases/mono-ADP-ribosyltransferases, or sirtuins. The
Rpd3/Hda1 family are further grouped into classes I, II, and
IV, while the sirtuins represent class III deacetylases [9, 29].
Due to the histone-centric nature of the founding studies
on acetylation, these acetylase and deacetylase enzymes are
traditionally referred to as HATs and HDACs. However,
research in the past 10 years has established that the so-
calledHATsandHDACshavemultiplenonhistoneandextra-
nuclear targets including, among many others, the tumor
suppressor p53, the oncogene β-catenin, and the molecular
chaperone HSP90 [30–33]. Accordingly, these enzymes are
now more generally referred to as lysine acetyltransferases
(KATs) and lysine deacetylases (KDACs).
Biochemically, the positively charged ε-amino group of
lysine residues is important for protein stability via hydrogen
bonding with nearby amino acid residues and can also serve
as a base during enzyme catalysis [34]( Figure 2). The cova-
lent enzymatic addition of an acetyl moiety to the ε-aminoJournal of Aging Research 3
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Figure 1: The cellular fates of acetyl-CoA. Please see section entitled “Acetyl-CoA and Metabolism” for a detailed description of the ﬁgure.
PDH: pyruvate dehydrogenase complex, AceCS2: acetyl-CoA synthetase 2, CS: citrate synthase, OA: oxaloacetate, AceCS1: acetyl-CoA
synthetase 1.
g r o u po nal y s i n er e s i d u ee ﬀectively neutralizes its native
positive charge, which changes its propensity to interact
with nearby residues, other proteins, or can alter the activity
of an enzyme. In its well-established chromatin context,
acetylation neutralizes positively charged lysine residues on
histone tails, thereby reducing their charged interactions
with chromatin and providing an epigenetic mark which is
recognized and used by bromodomain-containing proteins
to recruit transcriptional machinery and other chromatin-
modifying elements [1]. In another context, acetylation of
lysine 88 on the enzyme ornithine transcarbamylase (OTC)
changes its aﬃnity for its substrate, carbamoyl phosphate,
and negatively regulates the detoxiﬁcation of ammonia in
the urea cycle [35]. Additionally, acetylation of lysine 685
on STAT3 promotes its stable dimerization and subsequent
function as a transcriptional activator [36]. The ε-amino
groups of lysine residues are also the targets of a number
of other posttranslational modiﬁcations including methy-
lation, ubiquitination, SUMOylation, and NEDDylation.
These other modiﬁcations may confer their own unique
properties to proteins and protein functions that could be
coordinated with acetylation/deacetylation. Ubiquitination
of lysine residues, in particular, is known to cooperate
with acetylation to regulate the proteolytic degradation
of cellular proteins [37]. It has also been proposed that
acetylation may also act in concert with other distinct
posttranslational modiﬁcations to achieve a broad spectrum
of functional protein outcomes that has been termed the
“proteinmodiﬁcationcode,”analogoustothe“histonecode”
for transcriptional regulation [38]. In general, it has become
clear in recent years that Nε-acetylation is a widespread and
functionally diverse posttranslational modiﬁcation.
4. NAD+ De pe nd e ntDeac etylases(S irtuins)
In their traditional nuclear context, KATs catalyze the acetyl-
CoA-dependent addition of acetyl groups to disordered
histone tails—a mark that generally induces a “loose”
and transcriptionally active conformation of chromatin. In
contrast, the traditional functional understanding of KDACs
holds that they catalyze the H2O-dependent removal of
acetyl groups from histone tails to induce “tight” and tran-
scriptionally repressed chromatin [25]. This well-established
paradigm for transcriptional modulation was broadened
withthediscoveryofthemechanisticallydistinctsirtuinclass
of deacetylases/mono-ADP ribosyltransferases.
There are 7 mammalian sirtuin enzymes. The nuclear-
localized family members consist of SIRT1, SIRT6, and
SIRT7, while SIRT2 is concentrated in the cytosol [9]. Inter-
estingly, SIRT3, SIRT4, and SIRT5 exhibit mitochondrial
localization [9, 39, 40]. A recent report has also suggested
that SIRT1 could function within the mitochondria [41].
Together, the sirtuin family of KDACs are implicated in the
regulation of a broad scope of biological processes including,
but not limited to, transcriptional repression, develop-
ment, apoptosis, DNA repair, cellular stress responses, and4 Journal of Aging Research
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Figure 2: Changes in protein function and stability known to be associated with lysine acetylation. KATs: lysine acetyltransferases, KDACs:
lysine deacetylases.
metabolism [42–46]. Sirtuins are unique among the four
families of mammalian KDACs in that they catalyze the
removal of acetyl groups in a fashion that is dependent on
the cellular coenzyme NAD+. The reduced form of NAD+,
NADH, is generally produced during cellular catabolic
processes that serve to derive energy from nutrients, whereas
the oxidized form, NAD+, accumulates within cells during
nutrient scarce conditions. Thus, the ratio of the reduced
form to the oxidized form, or NAD+/NADH, is indicative of
the overall cellular energy state. Sirtuin deacetylase activity
is responsive to this measure of cellular energetic balance
and requires NAD+ as the acceptor of an acetyl group
from a target acetyl-lysine residue or for protein ADP
ribosylation[47].TheNAD+-dependentdeacetylasereaction
yields a deacetylated target protein, 2 -O-acetyl-ADP-ribose,
and nicotinamide, which can then act to inhibit the sirtuin
reaction mechanism [48]. In general, when the cellular
NAD+/NADH ratio is elevated during times of exercise,
nutrient restriction, or outright fasting, sirtuins are pre-
sumed to be more actively deacetylating their target proteins,
whereas during a fed or basal state, NADH predominates,
and sirtuins are less active. It is via their nutrient and
stress-sensing capacity to modify transcriptional landscapes
and modulate enzyme function that sirtuins are believed
to mediate the healthful beneﬁts of caloric restriction—
the only natural means of consistently extending lifespan
and delaying the onset of age-related pathologies such as
cancer in mammalian systems [8, 49–52]. It is the recently
understood and growing inﬂuence of the sirtuin family
on the biological mechanisms of aging that has excited
the research community and has made the sirtuins highly
attractive therapeutic targets for diseases of aging [53].
5. Mitochondrial Sirtuinsand Nε-Acetylation
Mitochondria are key organelles for intermediary metab-
olism as they coordinate the conversion of cellular carbon
sources into useable energy in the form of adenosine
triphosphate (ATP). The metabolic processes culminating
in ATP synthesis are well characterized and are regulated
by various mechanisms including nutrient availability, phos-
phorylation, allosteric mechanisms, reactive oxygen species,
and divalent cations such as calcium and magnesium [54–
57]. In light of the established understanding that mito-
chondria are the primary cellular generators of the acetyl-
CoA necessary for enzymatic acetylation, it is surprising that
Nε-acetylation within the mitochondria remained virtually
unstudieduntilthelastdecade.Thediscoverythatthesirtuin
family members SIRT3, SIRT4, and SIRT5 localize to the
mitochondrial matrix has strongly suggested that acetylation
could also play an important regulatory role within this
organelle [39, 40]. An early study by Shi et al. supported
this suggestion by demonstrating that SIRT3 regulates adap-
tive responses to cold exposure in brown adipose tissue
by increasing the expression of mitochondrial uncoupling
protein-1 (UCP1) and thereby increasing mitochondrial
respiration [58]. However, the data in this study were
generated with a SIRT3 construct lacking a mitochondrial
targeting sequence, and, thus, it is not clear whether the
results are due to SIRT3 acting within the mitochondria.
Soon after this study was published, Schwer et al. and Hal-
lows et al. independently conﬁrmed that mammalian SIRT3
directly regulates the activity of the mitochondrial protein
acetyl-CoA synthetase 2 (AceCS2) via NAD+-dependent
deacetylation [59, 60]. These ﬁndings demonstrated anJournal of Aging Research 5
ancient metabolic regulatory mechanism conserved from
the prokaryotic bacterium Salmonella enterica to mammals
[61]. Taken together, these early studies not only conﬁrmed
reversible Nε-acetylation as an important regulatory mark
within mitochondria but also implicated the sirtuins as key
nutrient-responsive modulators of the functional changes
acetylation confers upon its target proteins.
The initial studies of mitochondrial acetylation gave way
to global proteomics surveys. A 2006 proteomics survey
conducted by Kim et al. revealed that over 20% of liver
mitochondrial proteins and enzymes are acetylated and that
many change acetylation states in response to acute fasting
[2]. Furthermore, enzymes of the major mitochondrial
carbon conversion pathways such as the TCA cycle and β-
oxidation were found to be particularly enriched in acetyl
modiﬁcations.Theseﬁndingssuggestedthatreversibleacety-
lation could serve as a ﬁnely-tuned mechanism for globally
regulating the use and conversion of carbon energy sources.
The authors also demonstrated that a number of the mito-
chondrial enzymes they found to be acetylated have known
implications in processesofmammalianaging andlongevity,
such as manganese superoxide dismutase (MnSOD) and
NADH:ubiquinone oxidoreductase (respiratory complex I)
[2]. Complementing the discovery that global acetylation
proﬁles can change in response to nutrient availability,
Schwer et al. showed that global mitochondrial acetylation
proﬁles change in multiple organ systems in response to
long-term caloric restriction (CR) [62]. Surprisingly, this
study found that the vast majority of mitochondrial enzymes
exhibited increases in acetylation during caloric restriction,
whichcountersthebeliefthatsirtuin-mediateddeacetylation
mediates the beneﬁcial eﬀects of caloric restriction. This
ﬁnding could suggest that mitochondrial sirtuin-mediated
deacetylation plays a relatively minor role in the metabolic
changes that accompany caloric restriction and that there
are more complex and undiscovered adaptive mechanisms
at play. Additionally, Wang et al. and Zhao et al. further
conﬁrmedtheregulatoryimportanceofacetyl-modiﬁcations
in metabolism and in the coordination of cellular carbon
utilization [3, 63] .T h e s ep r o t e o m i cs u r v e y sh a v ee x p o s e d
the prevalence of acetylation within mitochondria and rein-
forced its importance as a regulatory modiﬁcation. Ongoing
studies that aimed at understanding the mechanisms of
acetylation dynamics are likely to reveal this as an essential
component of mitochondrial biology.
Further focused investigations of acetylation within
mitochondria have concentrated on the role of mitochon-
drial sirtuins. By generating SIRT3, SIRT4, and SIRT5 sys-
temicknockoutmousemodels,Lombardetal.demonstrated
that mice lacking SIRT3 exhibit global hyperacetylation of
mitochondrial proteins in liver and brown adipose tissue,
whereas the acetylation states in mice lacking SIRT4 and
SIRT5 were relatively unchanged [64]. This evidence sug-
gested that SIRT3 primarily functions as a deacetylase and
potentially targets a wide range of mitochondrial proteins,
whereas the deacetylase activities of SIRT4 and SIRT5 are
much more restricted.
Although it is widely accepted that SIRT3’s functional
role is predominantly within mitochondria, several studies
have explored potential nuclear and cytosolic roles for
this sirtuin family member. The study mentioned earlier
conducted by Shi et al. suggested that SIRT3 can regulate
theexpressionofthenuclear-encodedgenescodingformito-
chondrialuncouplingprotein1andperoxisomeproliferator-
activated receptor gamma coactivator 1-alpha (PGC-1α)
[58]. Similarly, SIRT3 has also been found to regulate the
expression of catalase and manganese superoxide dismutase
in the heart [65]. Yet another study indicated that SIRT3
can indirectly regulate the association between the glycolytic
enzyme hexokinase II and the mitochondria [66]. These
studies have formed the basis for future work investigating
potential roles for SIRT3 outside of the mitochondria.
Early characterization of SIRT3 null mice indicated that
they were phenotypically unremarkable, despite a signiﬁcant
reduction in their liver, heart, and kidney ATP content
associated with hyperacetylation and reduced activity of
mitochondrial respiratory complex I [7]. A more thorough
investigation, however, revealed that SIRT3−/− mice dis-
play hepatic lipid accumulation during fasting resembling
human disorders of fatty acid oxidation [4, 67]. This study
found that SIRT3 directly deacetylates and activates long-
chain acyl-CoA dehydrogenase(LCAD),illustrating a critical
mechanism for this sirtuin in the metabolic adaptations to
fasting and nutrient restriction [4]. Consistent with SIRT3’s
role in oxidative metabolism, Shulga et al. demonstrated that
SIRT3 can stimulate oxidative phosphorylation and a shift
away from glycolysis via inactivation of cyclophilin D, which
consequently destabilizes the association of hexokinase II
with the mitochondria [66]. Furthermore, mitochondrial
isocitrate dehydrogenase (IDH2) is deacetylated and acti-
vatedbySIRT3,therebyregulatingakeystepintheTCAcycle
as well as the supply of NADPH necessary for mitochondrial
antioxidant defense mechanisms [5, 68]. Additional studies
have exposed SIRT3 as a regulator of protein translation
via deacetylation of the mitochondrial ribosome and in the
activity of respiratory complex II (succinate dehydrogenase)
[69, 70]. It is now clear that SIRT3 can inﬂuence the activity
of oxidative phosphorylation, fatty acid oxidation, and the
TCA cycle, positioning this particular sirtuin as a major
player in the regulation of intermediary metabolism.
Studies of mitochondrial SIRT4 and SIRT5 are less
extensive than those for SIRT3. Earlier characterization
of mammalian SIRT4 revealed that it chieﬂy functions
as an NAD+-dependent mono-ADP-ribosyltransferase that
speciﬁcally ADP-ribosylates and inactivates mitochondrial
glutamate dehydrogenase (GDH), thereby regulating amino
acid-induced insulin secretion in pancreatic β cells [71, 72].
Later studies also identiﬁed GDH as a target of SIRT3-
mediated activation via deacetylation, but potential cross-
talk with SIRT4-mediated ADP ribosylation has not been
explored [5, 64]. Recently, it was demonstrated in vivo
that adenoviral-mediated shRNA knockdown of SIRT4 in
mouse liver increases the expression of genes involved in
fatty acid metabolism [73]. Together, these lines of evidence
suggest that SIRT4 could play an important role in the
disruption of lipid homeostasis associated with insulin
resistance in type 2 diabetes. Further characterization of
mitochondrial SIRT5 has shown that it regulates the ﬁrst6 Journal of Aging Research
step in the detoxiﬁcation of ammonia during the urea
cycle via deacetylation-mediated activation of carbamoyl-
phosphate synthetase 1 [6]. Accordingly, SIRT5−/− mice
develop hyperammonemia during metabolic states demand-
ing greater protein catabolism such as fasting and caloric
restriction [6, 74]. Another investigation has suggested that
SIRT5 can deacetylate cytochrome c, a protein involved
in mitochondrial respiration and apoptosis [5]. However,
the functional importance of this relationship has not
been determined and is also inconsistent with ﬁndings in
the previously mentioned study indicating that SIRT5 is
localized to the mitochondrial matrix. Future studies of
mitochondrial sirtuins 4 and 5 are likely to elucidate their
fullregulatorycapacityinresponsetovariouscellularstresses
and stimuli.
Interestingly, other studies have implicated reversible
mitochondrial acetylation in mechanisms of cell growth
and survival. An early investigation of SIRT3’s function in
an epithelial cancer cell line indicated that it is required
for JNK-regulated cell death via silencing the apoptotic
regulator B-cell lymphoma 2 (bcl-2) [75]. In contrast to
its role in epithelial cancer, SIRT3 was shown to serve a
prosurvival function in cardiomyocytes via deacetylating
Ku70 and promoting the sequestration of the proapoptotic
protein Bax [43]. In addition to its apoptotic functions,
SIRT3 was more recently demonstrated to be a bona ﬁde
t u m o rs u p p r e s s o rb yK i me ta l .[ 76]. This study showed
that SIRT3−/− mouse embryonic ﬁbroblasts display reduced
antioxidant defenses, which result in a lower threshold
for tumorigenesis—a ﬁnding that conﬁrmed earlier work
that established SIRT3’s involvement in the transcriptional
regulation of antioxidant genes [65, 77]. Furthermore, the
transformation-permissive eﬀect of SIRT3 ablation can be
reversed upon the addition of exogenous MnSOD [76].
Consistent with these ﬁndings, two more recently published
investigations independently conﬁrmed that SIRT3 directly
deacetylates and activates MnSOD, thereby linking nutrient
availability to antioxidant defenses [78, 79]. A diﬀerent
study conducted by Yang et al. established that the levels
of mitochondrial NAD+ are a critical determinant to cell
survival [80]. Mitochondrial NAD+ levels were shown to be
regulated by the rate-limiting enzyme in the mammalian
NAD+-salvage pathway, nicotinamide phosphoribosyltrans-
ferase (Nampt). Importantly, the authors demonstrated
that NAD+-responsive mitochondrial SIRT3 and SIRT4 are
required for improved cell survival when mitochondrial
NAD+ levels rise under conditions of fasting and induced
genotoxic stress [80]. Recently, two independent approaches
also implicated SIRT3 in the regulation of p53-mediated
growth arrest [81, 82]. Taken together, these studies indicate
thatmitochondrial SIRT3is acritical mediator ofcellgrowth
and survival which may hold therapeutic implications in the
treatment of various cancers.
There are also several interesting acetylated mitochon-
drial proteins involved in cellular stress responses and
apoptosis on which the eﬀect of reversible acetylation
has not been studied. These proteins include apoptosis-
inducing factor (AIF) responsible for DNA fragmentation
during apoptosis, cytochrome c which forms an important
component of the apoptosome as well as voltage-dependent
anion channel (VDAC) and adenine nucleotide translocase
(ANT), both of which are believed to form the mitochon-
drial permeability transition pore during apoptosis [2, 83].
Furthermore, all of the previously mentioned mitochondrial
proteins are reversibly acetylated in a nutrient-sensitive
manner, suggesting that the apoptotic functions of these
proteins may be regulated by cellular energy status [2]. The
study of mitochondrial acetylation states in processes of cell
death and survival represents an entirely open ﬁeld of study
that is rife with intriguing biological questions that could
provide a new layer of understanding to the mechanisms and
regulation of apoptosis and cell growth.
The majority of the studies in the ﬁeld of mitochondrial
acetylation thus far have focused on the mitochondrial
localized members of the sirtuin family of deacetylases,
while the search for the counterbalancing mitochondrial
acetyltransferase(s) has so far been unsuccessful. Although it
is possible that certain nuclear-encoded, mitochondrial tar-
geted proteins acquire acetylation marks prior to mitochon-
drial import, the conﬁrmed acetylation of the mitochondrial
conﬁned ATP synthase subunit 8 protein makes the existence
of a mitochondrial acetyltransferase(s) highly likely [2, 83].
The marked enrichment of acetyl-modiﬁcations occurring
on enzymes involved in major processes such as β-oxidation
andredoxchemistry(64%and44%,resp.)overthetotalpool
of acetylated mitochondrial proteins (22%) also suggests
ﬁnely tuned enzymatic mechanisms for regulating carbon
ﬂux within mitochondria [2]. Furthermore, the amino acid
sequence motifs favoring acetylation within mitochondria
diﬀer from those of the nucleus and cytosol, suggesting
a mitochondrial-speciﬁc acetyltransferase(s) possessing its
owndistinctsetofsubstrates[2].Despitethestrongevidence
for a mitochondrial acetyltransferase(s), it is also important
to consider the possibility of nonenzymatic acetylation
occurring in response to changes in the overall mitochon-
drial acetyl-CoA pool. Indeed, nonenzymatic acetylation is
known to occur on histone substrates and may account for
the unexpected increases in mitochondrial acetylation in
response to caloric restriction [62, 84].
How do large changes in the acetylation state of a
given mitochondrial protein pool aﬀect protein function?
Furthermore, how do large-scale changes in global mito-
chondrial acetylation states inﬂuence mitochondrial biology
and overall cellular energy status? Although little work has
beenconductedtoaddressthesequestions,someinsightscan
be drawn from the literature. In the work of Hirschey et al.,
the authors performed semiquantitative mass spectrometry
of the fatty acid oxidation protein LCAD in wild-type
and SIRT3−/− livers in an eﬀort to identify diﬀerentially
acetylated lysine residues of interest [4]. The analysis dis-
covered eight acetylation sites on LCAD; however, only
one particular acetyl-lysine residue, K42, was found to be
critically important for the SIRT3-dependent modulation
of LCAD’s enzymatic activity. Constitutively mimicking de-
acetylation at K42 induced a nearly 60% increase in LCAD
activity. Furthermore, acetylation at only K42 accounted
for over 70% of the total LCAD acetyl-lysine signal in
SIRT3−/− liver mitochondria as quantiﬁed by Western blotJournal of Aging Research 7
densitometry. Earlier work performed by this group found
a similar pattern with K642 of the mitochondrial enzyme
acetyl-CoA synthetase 2 [59]. These ﬁndings suggest that
large changes in acetylation signal and protein function
could be induced by relatively limited or restricted changes
in the acetylation state of a given protein. Accordingly,
global changes in mitochondrial acetylation, such as those
observed in the SIRT3−/− mitochondria, might represent an
unexpectedly limited number of acetylation state changes
corresponding to large functional and metabolic conse-
quences. Future work in this ﬁeld will surely provide exciting
insights into these questions, and the imminent discovery
of the mitochondrial acetyltransferases(s) or alternative
acetylation mechanisms will provide a critical step toward a
more complete understanding of mitochondrial acetylation
biology and its implications for disease states.
6. MitochondrialAcetylation andHeartFailure
The recently understood prevalence of acetyl modiﬁcations
within the mitochondria that can potentially modulate
processes of intermediary metabolism suggests that altered
acetylation could potentially contribute to age-associated
disease states in which there are recognized alterations in
mitochondrial carbon utilization, such as heart failure and
cancer.
The unfortunate progression from increased cardiac
workload to pathological cardiac hypertrophy and, ulti-
mately, heart failure occurs when the long-term metabolic
demands of the body exceed the ability of the pumping
heart to meet them. Although there are a number of human
conditions capable of leading to heart failure including renal
insuﬃciency, high blood pressure, and cardiac arrhythmias,
the leading risk factor is increasing age [85] .T h er o l eo f
mitochondrial dysfunction in heart failure and the aging
process in general is well established. Mitochondrial dis-
orders are often characterized by myopathies of the heart
and skeletal muscle, as these highly energetic organs are
heavily dependent on mitochondria-derived energy gener-
ation [86]. Furthermore, cardiomyopathy and heart failure
in the general population are often regarded as diseases of
impaired energy homeostasis associated with a depletion
of the cardiomyocyte ATP and creatine pools [87, 88].
Interestingly, mice lacking the predominant mitochondrial
NAD+-dependent deacetylase SIRT3 also exhibit depleted
cardiac ATP levels and further display global hyperacetyla-
tion of mitochondrial proteins in liver and brown adipose
tissue [7, 64]. These data suggest a role for mitochon-
drial SIRT3 dysfunction in the pathophysiology of heart
failure. Several additional studies also stand in support of
this notion. As discussed earlier, Sundaresan et al. have
shown that SIRT3 promotes cardiomyocyte cell survival
during genotoxic and oxidative stress [43]. This group has
also revealed that SIRT3 transgenic mice are resistant to
agonist-induced cardiac hypertrophy via SIRT3-mediated
upregulationofantioxidantgenes[65].Moreover,exogenous
administration of NAD+ into the hearts of mice was
found to abrogate agonist-induced cardiac hypertrophy in
a SIRT3-dependent manner [89]. Similarly, transgenic mice
harboring cardiac-speciﬁc overexpression of the NAD+-
salvaging enzyme Nampt display reduced infarct size follow-
ing ischemia-reperfusion injury, raising the possibility that
the cardioprotective eﬀect of increased NAD+ is mediated by
the mitochondrial sirtuins [90]. Pathophysiological cardiac
remodeling and heart failure in humans are also known to
develop in response to alterations in the renin-angiotensin
system (RAS) [91]. One of the RAS signaling proteins,
angiotensin II, is often used to induce hypertension and
cardiac hypertrophy in experimental animals. Interestingly,
ablation of the angiotensin II type I receptor in mice
reduces cardiac injury, increases lifespan, and upregulates
the expression of SIRT3 and its upstream regulator Nampt
in the kidney [92]. Collectively, these studies implicate the
mitochondrial deacetylase SIRT3 as a major cardioprotective
enzyme, the modulation of which may hold therapeutic
promise in the treatment of cardiac disease.
Mitochondrial oxidative phosphorylation is responsible
for generating over 90% of the energy-rich ATP in the
adult human heart [93, 94]. Under basal conditions, as
much as 70% of this ATP is derived from fatty acid β-
oxidation,andtheremainderisgeneratedfromtheoxidation
of glucose, lactate, and ketone bodies [95]. The energetic
substrate preferences of the heart can change in response to
acute stimuli or stressors such as exercise, energy demand,
hormonal regulation, ischemia, and substrate availability
[95, 96]. Thus, the healthy heart is a versatile and adaptive
consumer of energy substrates. The failing heart, however,
experiences complex alterations in energy metabolism and
substrate utilization that are incompletely understood [97].
Studies on rodent and canine models generally indicate
that the failing myocardium suﬀers downregulation of mito-
chondrial respiratory chain complexes, decreased oxygen
consumption and ATP generation, decreased ﬂux through
the creatine kinase system, and impaired fatty acid oxidation
[95, 97–100]. Many have proposed targeting these metabolic
rearrangements and altering substrate utilization as a ther-
apeutic strategy to treat heart failure [101]. Interestingly,
numerous mitochondrial enzymes of the respiratory chain
and those involved in the oxidation of glucose and fat
carry one or more acetylation marks that are reversible
in a nutrient-sensitive manner. These include respiratory
complexes I, II, and V, pyruvate dehydrogenase, several acyl-
CoA dehydrogenases, and carnitine palmitoyltransferase 1
and 2, among many others [2, 62, 83]. It has also been
demonstrated that the mitochondrial deacetylase SIRT3 can
directly promote oxidative metabolism via deacetylation-
mediated activation of respiratory complex 1, long-chain
acyl-CoA dehydrogenase (LCAD), and cyclophilin D as
discussed earlier [4, 7, 66]. The notion that acetylation
within the mitochondria can modulate the activity of
metabolic enzymes implies that there may be altered acety-
lation states within the mitochondria and that they could
contribute to the pathophysiology of heart failure. More
importantly, if this is true, devising strategies that directly
target mitochondrial acetylation may provide therapeutic
beneﬁt in pathological rearrangements of cardiac energy
metabolism.8 Journal of Aging Research
7. MitochondrialAcetylation andCancer
In 1924, Warburg and Negelein made the seminal obser-
vation that many cancer cells prefer to metabolize glucose
into lactate even in the presence of suﬃcient oxygen to
support mitochondrial oxidative phosphorylation [102].
Thisphenomenon,knownasthe“WarburgEﬀect”oraerobic
glycolysis, was hypothesized by Warburg to be a defect in
the mitochondrial metabolism of tumor cells [103]. In the
roughly 70 years following its discovery, little progress was
madeinuncoveringthebiochemicalmechanismsunderlying
the propensity of tumor cells to prefer aerobic glycolysis. The
last 15 years of oncology research, however, have experienced
a renewed interest in understanding the Warburg Eﬀect, and
a number of important discoveries have been made. Notably,
it has been observed that tumor cell lines almost exclusively
express the embryonic isoform of the glycolytic enzyme
pyruvate kinase (PKM2), which contributes to the glycolytic
preference and lactate production observed in cancer cells
[104, 105]. Recent work conducted by Vander Heiden et al.
has even provided early evidence of an alternative carbon
utilization pathway in tumors expressing PKM2 [106]. Fur-
ther work on tumor metabolism has revealed that malignant
cells also consume large amounts of glutamine in an eﬀort
to replenish the TCA cycle intermediates necessary for a
high rate of macromolecular synthesis that is characteristic
ofrapidlyproliferatingcells[107].This“glutamineaddition”
can partially be explained by induction of a transcriptional
program that favors glutaminolysis via the activation of the
proto-oncogene Myc, which can occur in many forms of
human cancers including neuroblastoma, lymphoma, and
small cell lung cancer [108–112]. Together, these studies and
the recent revitalized interest in cancer bioenergetics have
unveiled some key mechanisms underlying the remarkable
abilityoftransformedcellstoproliferate.Despitetheserecent
advances,thereisstillmuchthatwedonotunderstandabout
a tumor cell’s aptitude for reprogramming metabolism to
meet its rapid growth demands, and this represents an active
area of investigation.
Orchestrating malignant changes in cellular behavior
oftenoccursatthelevelofposttranslationregulation.Indeed,
many cancers are characterized by mutations in, or altered
activityof,certainkinasesincludingtumorsuppressorLKB1,
Src, phosphatidylinositol-3-kinase (PI3K), and the mutant
BCR-ABL fusion kinase, which often occurs in chronic myel-
ogenous leukemia (CML) [113–116]. Additionally, there
is an appreciated role for cancer-associated transcriptional
changes mediated by nuclear KATs and KDACs [26, 117].
Interestingly, the predominant mitochondrial deacetylase
SIRT3 has recently been reported to function as a tumor
suppressor [76]. This work demonstrated that SIRT3−/−
ﬁbroblasts exogenously transformed with the oncogenes
Myc and Ras display reduced activity of mitochondrial
respiratory complexes I and III [76]. These results are
consistent with earlier work demonstrating direct acti-
vation of mitochondrial complex I via SIRT3-mediated
deacetylation [7]. Moreover, these ﬁndings suggest that
there is impaired oxidative phosphorylation and a heavier
reliance on glycolytic metabolism in order to satisfy the
energetic requirements of transformed SIRT3−/− ﬁbroblasts,
representing the primary hallmarks of the Warburg Eﬀect.
Coupling these ﬁndings with the knowledge that SIRT3
could potentially be regulating numerous mitochondrial
proteins suggests that SIRT3 dysfunction may represent an
important factor contributing to the poorly understood
metabolic reprogramming that occurs during tumorigenesis
[64]. Consistent with this notion, SIRT3 is known to be
downregulated in certain breast cancers [76]. Furthermore,
if SIRT3 can function as a tumor suppressor, it is logical to
conceive that the putative mitochondrial acetyltransferase(s)
counterbalancing the tumor-suppressive eﬀects of SIRT3
would be characterized as oncogene(s). A multitude of
mitochondrial proteins are now known to be acetylated,
many of which are modiﬁed in a reversible and nutrient-
responsive manner. Accordingly, alterations in mitochon-
drialacetylationstates,and,hence,alterationsincarbonsub-
strate utilization, may contribute to the unusual preference
for aerobic glycolysis and glutaminolysis often observed in
numerous forms of cancer.
In addition to understanding the emerging importance
of mitochondrial acetylation in age-associated diseases, it is
also important to brieﬂy discuss evidence for its involvement
in the aging process in general. Heart failure and cancer are
two pathophysiological states that display an exponentially
increasing incidence with advancing age, and a role for
the mitochondrial deacetylase SIRT3 in these respective
conditions has been discussed [85]. Complementing SIRT3’s
emerging role in diseases of aging is the interesting though
controversial observation that SIRT3 is the only member of
the sirtuin family reportedly linked to longevity in humans.
An early study of the human SIRT3 gene identiﬁed a guanine
to thymine (G477T) single nucleotide polymorphism (SNP)
located in exon three to be associated with survivorship
in elderly males [118]. Later, Bellizzi et al. discovered a
variable number of tandem repeat (VNTR) polymorphisms
possessing enhancer activity at the SIRT3 locus [119]. The
authors of this study further demonstrated that the inactive
form of the SIRT3 enhancer is underrepresented in a
population exceeding 90 years of age, and thus concluded
that the active VNTR enhancer is associated with longevity.
Additional work has identiﬁed the activating elements that
bind to this intronic VNTR enhancer sequence [120]. In
contrast to these studies, a meta-analysis of SIRT3 SNP
data coupled with a larger association study of the SIRT3
chromosomal region in centenarians indicated no signiﬁcant
genomic variation that could be linked to longevity, with
the exception of one possible SNP, rs939915 [121]. Future
analysisofgenomicvariationatthemammalianSIRT3locus,
transgenic animals, and functional studies of SIRT3 and its
deacetylation targets will provide much-needed insight into
the possible role that this sirtuin plays in longevity and the
aging process.
8. Summary
Although the acetylation of lysine residues has been known
as a posttranslational modiﬁcation for over 40 years, it
was not until the last 15 years that advances in technologyJournal of Aging Research 9
and molecular techniques have enabled the rigorous study
of this highly interesting regulatory mechanism. We now
understand that lysine acetylation rivals phosphorylation,
in respect to both the sheer number of acetylated proteins
in mammalian cells as well as in its regulatory capacity.
Furthermore, global cellular acetylation states are largely
dependent on mitochondrial-derived processes of acetyl-
CoA formation. Many proteins within the mitochondria,
itself, are now known to be reversibly acetylated and, in
some cases, acetylation can regulate metabolism and the
fate of carbon energy sources. Thus, reversible acetylation
of mitochondrial proteins represents a new layer of protein
regulation mediating acute and adaptive changes in mam-
malian metabolism. This new framework for understanding
metabolism suggests that altered mitochondrial acetylation
patterns can contribute to the pathological shifts in energy
generation that are known to occur during heart failure, the
rapid proliferation of malignant tumor cells, and, indeed,
the aging process in general. It is also worth noting that
mitochondrial acetylation in neurodegenerative pathologies
is currently an unstudied area. Mitochondrial acetylation
biology is an infant ﬁeld of study that, in the future, will
have the potential to bridge our understanding of cellular
metabolism, cell death and survival, and the inevitable
pathological consequences of aging.
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